CALL - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 01:45:54 27/06/2024 pm IST | ||
| 46.86 EUR | +0.41% |
|
| Current month | +21.76% | ||
| 1 month | +22.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 46.86 | +0.41% |
| 26/24/26 | 46.67 | -0.58% |
| 25/24/25 | 46.94 | +0.88% |
| 24/24/24 | 46.53 | +2.33% |
| 21/24/21 | 45.47 | +2.25% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 01:45 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6FAK |
| ISIN | DE000VU6FAK3 |
| Date issued | 18/04/2023 |
| Strike | 401.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.77 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 47.43 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.34 € |
| Spread % | 0.72% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
